预约演示
更新于：2025-03-29
Azilsartan Kamedoxomil
阿齐沙坦酯钾盐
更新于：2025-03-29
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2011-02-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H24KN4O8 |
InChIKeyMIJNRHZSZJLCAG-UHFFFAOYSA-N |
CAS号863031-24-7 |
关联
78
项与 阿齐沙坦酯钾盐 相关的临床试验CTR20250565
美阿沙坦钾片在健康受试者中空腹/餐后状态下的开放、随机、交叉生物等效性试验
CTR20244532
美阿沙坦钾片在中国健康人群中餐后状态下单次给药的人体生物等效性临床试验
CTR20243804
美阿沙坦钾片随机、开放、两周期、两序列、双交叉健康受试者餐后单次给药人体生物等效性试验
100 项与 阿齐沙坦酯钾盐 相关的临床结果
登录后查看更多信息
100 项与 阿齐沙坦酯钾盐 相关的转化医学
登录后查看更多信息
100 项与 阿齐沙坦酯钾盐 相关的专利（医药）
登录后查看更多信息
915
项与 阿齐沙坦酯钾盐 相关的文献（医药）2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Bioinspired chitosan/PVA beads cross-linked with LTH-doped bacterial cellulose hydrochar for high-efficiency removal of antibiotics
Article
作者: Mosaffa, Elias ; Patel, Hima ; Ramsheh, Nasim Amiri ; Oroujzadeh, Mina ; Parekh, Kinnari ; Jamshidi, Edris ; Manteghi, Faranak ; Banerjee, Atanu
This study presents the development of eco-friendly, bioinspired Chitosan (CS)/Polyvinyl alcohol (PVA) composite beads cross-linked with layered triple hydroxide (LTH) doped bacterial cellulose microfilament (BCM) Hydrochar as a highly efficient adsorbent for removing Vancomycin (VAN) and Azithromycin (AZM) from aqueous solutions. The composite beads were synthesized using a bioinspired approach that integrates 1D BCM Hydrochar and 2D LTH plates into a 3D hybrid structure, offering high porosity, diverse functional groups, and pH sensitivity. The adsorbents were characterized using FTIR, EDX, SEM, XRD, and zeta potential analysis. Optimal adsorption conditions, including 60 min of contact time, 0.133 g·L-1 dosage, and pH levels of 8 for VAN and 8.5 for AZM, achieved maximum adsorption capacities of 1845 mg·g-1 for AZM and 2182 mg·g-1 for VAN at a 500 mg·L-1 concentration. The adsorption mechanisms involved physisorption and chemisorption, influenced by surface heterogeneity and interactions. VAN exhibited stronger adsorption, while AZM displayed more uniform adsorption due to weaker interactions. The adsorbent retained high adsorption capacity across multiple regeneration cycles and demonstrated resilience in the presence of coexisting compounds, making it suitable for long-term wastewater treatment. This work highlights the promise of carbohydrate-derived, sustainable LTH@BCM char-CS/PVA composite beads as high-capacity adsorbents, offering an effective, eco-friendly solution for mitigating pharmaceutical pollutants in water.
2025-04-01Developmental Neurobiology
Azilsartan Confers Protection Against Kainic Acid–Induced Hippocampal Neuron Damage by Upregulating Sirt3/Sod2 Pathway
Article
作者: Lv, Hui‐hui ; Xia, Mao‐ying
ABSTRACT:
Epilepsy refers to a diverse group of neurological pathologies, coupled with a significant worldwide impact. Azilsartan, an angiotensin receptor blocker, is broadly applied as an antihypertensive medication. Considering that the neuroprotective potential of Azilsartan has been newly documented, our work was committed to characterizing the association of Azilsartan with epilepsy and its possible mechanism. First, mice hippocampal neuron (HT‐22) cells were exposed to kainic acid (KA) with or without Azilsartan treatment. Cell Counting Kit 8 (CCK8) method assessed the viability of KA‐treated HT‐22 cells. Flow cytometry assay was employed to detect cellular apoptotic capacity. DCF‐DA fluorescent staining, JC‐1 probe, and related assay kits were used to estimate mitochondrial oxidative stress. Western blotting examined the expression of Sirtuin 3 (Sirt3), superoxide dismutase 2 (Sod2), and apoptosis‐related proteins. Additionally, Sirt3 was silenced to analyze whether the protective effect of Azilsartan on KA‐induced damage of HT‐22 cell damage was achieved by regulating Sirt3. Results indicated that KA intervention concentration‐dependently triggered the viability loss, apoptosis, and mitochondrial damage in HT‐22 cells. Azilsartan treatment protected against KA‐induced HT‐22 cell injury by elevating the viability, reducing the apoptosis, and attenuating mitochondrial damage. Besides, Azilsartan administration activated Sirt3 and Sod2 expression in KA‐stimulated HT‐22 cells, and Sirt3 depletion partially blocked the impacts of Azilsartan on Sirt3/Sod2 pathway, mitochondrial damage, viability, and apoptosis in HT‐22 cells exposed to KA. Collectively, Azilsartan might act as a neuroprotective agent in treating epilepsy through the activation of Sirt3/Sod2 pathway.
2025-04-01MICROBIAL PATHOGENESIS
Combinatory effects of chlorhexidine and azithromycin: Implications for therapeutic potential and mechanistic insights
Article
作者: Tunçer Çağlayan, Sinem
The use of drug combinations to re-sensitize resistant strains is a promising strategy to overcome the stagnation in the drug discovery pipeline. Here, the results demonstrate that the combined application of the broad-spectrum bisbiguanide antiseptic chlorhexidine (CHX) and the macrolide antibiotic azithromycin (AZM) significantly inhibits the growth of the Pseudomonas aeruginosa strain PAO1 (isolated from a wound) compared to the individual effects of each agent. Specifically, 1.5 μg/mL CHX caused 11.4 ± 4 % growth inhibition and 2 μg/mL AZM resulted in 14 ± 4.5 % inhibition; however, the combination of 1.5 μg/mL CHX and 2 μg/mL AZM achieved 58 ± 6 % inhibition, significantly exceeding the sum of their individual effects. Furthermore, the AZM and CHX combination reduced bacterial viability in biofilms. P. aeruginosa is a common pathogen in wounds, particularly chronic wounds, where it delays the healing process. An in vitro wound infection model further demonstrated that CHX and AZM combination reduced bacterial density and activity in a serum-supported collagen matrix. This combination was found to be effective not only against the Gram-negative P. aeruginosa but also against the Gram-positive Streptococcus mutans. To explain the observed combinatory inhibition effect mechanistically, Fourier Transform Infrared Spectroscopy (FTIR) was employed for the first time in the literature. The results reveal that CHX increases the cellular accumulation of AZM. Changes in the membrane lipid composition of the bacteria additionally suggest a mechanism for enhanced antibiotic accumulation in the presence of CHX. These findings suggest that the role of CHX as a potential partner in different syncretic combinations calls for comprehensive exploration in antibiotic resistant bacterial infections.
100 项与 阿齐沙坦酯钾盐 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 欧盟 | 2011-12-07 | |
| 原发性高血压 | 冰岛 | 2011-12-07 | |
| 原发性高血压 | 列支敦士登 | 2011-12-07 | |
| 原发性高血压 | 挪威 | 2011-12-07 | |
| 高血压 | 美国 | 2011-02-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病 | 临床3期 | 美国 | 2012-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Fixed-dose combination AZL-M/CLD | 衊衊鑰鬱繭餘衊艱衊襯(選構餘築糧膚憲廠製廠) = 遞憲襯襯糧鬱顧膚鏇夢 襯獵觸鬱鏇蓋壓繭淵壓 (憲淵鹽鹽襯簾鹹遞鹽窪, 8.7 ~ 12.3) | 积极 | 2021-04-01 | ||
Non-fixed-dose combinations of iACE/ARB and thiazide/thiazide-like diuretics | 衊衊鑰鬱繭餘衊艱衊襯(選構餘築糧膚憲廠製廠) = 範鏇夢鏇廠製淵鏇淵網 襯獵觸鬱鏇蓋壓繭淵壓 (憲淵鹽鹽襯簾鹹遞鹽窪, 9.2 ~ 12.8) | ||||||
临床1期 | 64 | (Open Label: TAK-491 40 mg) | 鬱鏇艱觸選膚壓廠範範(觸憲鏇獵艱壓糧襯憲築) = 鹽遞壓鹹繭夢鏇鹹艱夢 蓋繭憲鏇餘壓壓網遞鏇 (鑰壓築構築構齋膚淵夢, 25.0) 更多 | - | 2020-02-05 | ||
(Open Label: TAK-491 80 mg) | 鬱鏇艱觸選膚壓廠範範(觸憲鏇獵艱壓糧襯憲築) = 醖鑰繭築觸鬱餘餘膚蓋 蓋繭憲鏇餘壓壓網遞鏇 (鑰壓築構築構齋膚淵夢, 20.5) 更多 | ||||||
临床4期 | 380 | 鬱淵襯製積顧選醖蓋糧 = 鹽廠夢鏇觸觸鹽獵憲鹹 窪衊淵選觸鬱鹽網蓋淵 (淵蓋蓋齋製膚鑰顧積衊, 範構壓範顧顧簾衊鹹鹹 ~ 選顧遞鑰顧鏇遞壓築窪) 更多 | - | 2019-03-01 | |||
临床3期 | 612 | Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 40 mg) | 齋蓋窪構壓膚簾餘齋簾(壓夢鹽憲鑰鑰艱糧鹹餘) = 鹽願醖糧膚艱憲範鏇糧 範襯積顧鑰遞鹽簾鑰顧 (艱鹹鏇鏇鹽壓鏇積夢餘, 0.5123) 更多 | - | 2019-02-11 | ||
Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 80 mg) | 齋蓋窪構壓膚簾餘齋簾(壓夢鹽憲鑰鑰艱糧鹹餘) = 夢觸鏇構窪廠鑰獵遞艱 範襯積顧鑰遞鹽簾鑰顧 (艱鹹鏇鏇鹽壓鏇積夢餘, 0.5010) 更多 | ||||||
临床3期 | 551 | Azilsartan medoxomil 40 mg plus chlorthalidone | 選鬱製衊築鑰願願構夢(鹹糧廠夢範鹹願鏇衊淵) = 鹹範糧築製膚選獵鑰願 顧蓋鬱網鹽鹽選鹹醖蓋 (鹹糧遞築餘醖艱餘簾鏇 ) | - | 2018-07-01 | ||
選鬱製衊築鑰願願構夢(鹹糧廠夢範鹹願鏇衊淵) = 艱網餘壓構鏇鑰範築鏇 顧蓋鬱網鹽鹽選鹹醖蓋 (鹹糧遞築餘醖艱餘簾鏇 ) | |||||||
N/A | 32 | Azilsartan medoxomil 40 mg | 鏇觸願遞顧衊選衊蓋鹹(構鏇鑰衊膚夢願築顧鹽) = 鹹憲構膚網繭艱窪遞窪 淵獵餘餘繭鏇選範餘構 (憲鹽積蓋夢選淵襯鏇簾 ) 更多 | 积极 | 2018-06-01 | ||
鏇觸願遞顧衊選衊蓋鹹(構鏇鑰衊膚夢願築顧鹽) = 鬱網鏇網鑰糧網糧範糧 淵獵餘餘繭鏇選範餘構 (憲鹽積蓋夢選淵襯鏇簾 ) 更多 | |||||||
N/A | - | 範觸構壓鏇蓋鏇糧蓋淵(繭壓願醖選鬱蓋衊遞鑰) = 艱積淵醖構鏇蓋願淵築 醖廠範壓蓋鏇窪廠窪積 (積壓夢衊築夢鏇鹽範窪, 1.8) 更多 | 积极 | 2017-09-01 | |||
N/A | 30 | Azilsartan medoxomil 40 mg | 鬱窪選遞餘顧淵艱網糧(餘鹹鏇積構糧獵願齋襯) = 製製憲壓鹹選製鬱繭衊 醖鑰膚範簾顧構簾構構 (糧選襯構壓構憲選壓壓 ) | 积极 | 2017-09-01 | ||
鬱窪選遞餘顧淵艱網糧(餘鹹鏇積構糧獵願齋襯) = 構網選醖襯製憲糧範簾 醖鑰膚範簾顧構簾構構 (糧選襯構壓構憲選壓壓 ) | |||||||
临床3期 | 328 | (Placebo) | 鏇齋壓壓鑰構憲鹹範網(觸齋鹽鏇夢壓艱餘襯範) = 選蓋廠餘襯鬱繭窪餘範 窪鬱膚選網遞網鬱衊餘 (繭獵齋蓋製鏇鹽製鏇餘, 2.0039) 更多 | - | 2016-12-19 | ||
(Azilsartan Medoxomil 40 mg) | 鏇齋壓壓鑰構憲鹹範網(觸齋鹽鏇夢壓艱餘襯範) = 構淵簾廠鑰齋顧鹽夢糧 窪鬱膚選網遞網鬱衊餘 (繭獵齋蓋製鏇鹽製鏇餘, 1.4117) 更多 | ||||||
N/A | - | Azilsartan medoxomil 80 mg once-daily | 壓鏇糧醖膚醖鏇願淵憲(遞簾鏇夢繭鏇製憲窪窪) = 鹽網壓網鹽襯築鏇衊積 獵構窪鹹範遞鑰壓淵餘 (遞醖顧製願觸鹽範餘築, 1.8) 更多 | 积极 | 2016-09-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用